Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 6. (Record no. 130346)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06457nam a22004693i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC5044184 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729131448.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2017 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781681083391 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781681083407 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC5044184 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL5044184 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11441973 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1006418198 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC523.A883 2017 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.83100000000002 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Atta-ur-Rahman. |
| 245 10 - TITLE STATEMENT | |
| Title | Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 6. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Sharjah : |
| Name of producer, publisher, distributor, manufacturer | Bentham Science Publishers, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2017. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2017. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (207 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Frontiers in Clinical Drug Research - Alzheimer Disorders ; |
| Volume/sequential designation | v.6 |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- CONTENTS -- PREFACE -- List of Contributors -- The Treatment of Brain Inflammation in Alzheimer's Disease. Can Traditional Medicines Help? -- James David Adams* -- INTRODUCTION -- Anti-inflammatory Agents in AD -- Risk Factors for Developing AD -- Prevention of AD -- Ceramide and AD -- The Blood Brain Barrier and AD -- Visfatin and AD -- Traditional Plant Medicines for AD -- The Modern Approach to Curing AD -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Stem Cell Strategies for the Modeling and Therapy of Alzheimer's Disease -- Haigang Gu* -- 1. INTRODUCTION -- 2. NEUROPATHOLOGY OF AD: KEYS TO DRUG DISCOVERY AND ANIMAL MODELS -- The β-amyloid Hypothesis of AD -- The Hyper-phosphorylated Tau Protein Hypothesis of AD -- The cholinergic hypothesis of AD -- 2.1. Drug Discovery of AD -- 2.1.1. Treatment of Amyloid Pathology -- 2.1.2. Treatment of Tau Pathology -- 2.1.3. Treatment of Synaptic Dysfunction -- 2.1.4. Neurotrophic Factors (NTFs) -- 2.1.5. Cell Transplantation -- 2.2. Animal Models of AD -- 2.2.1. Transgenic Animal Models of AD -- 2.2.2. Selective Cholinergic Lesion Animal Models of AD -- 3. STEM CELLS AS USEFUL TOOLS FOR CELL TRANSPLANTATION, DRUG DISCOVERY AND AD MODELING -- 3.1. Neural Stem/Progenitor Cells (NP/SCs) -- 3.2. Mesenchymal Stem Cells (MSCs) -- 3.3. Embryonic Stem Cells (ESCs) -- 3.4. Induced Pluripotent Stem Cells (IPSCs) -- 3.5. In Situ Generation of Neurons in the Brain -- 3.6. Modeling and Therapy of AD with Genome Editing -- 4. PERSPECTIVES -- ABBREVIATIONS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Retinal Neurodegeneration in Alzheimer's Disease -- L. Guo1, M. Pahlitzsch#, 1, F. Javaid#, 1 and M.F. Cordeiro*, 1, 2 -- INTRODUCTION -- THE RETINA - AN INTEGRAL PART OF THE BRAIN -- VISUAL CHANGES IN AD -- Visual Abnormalities -- Pupil Abnormalities. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | RETINAL CHANGES IN AD -- Retinal Histopathologic Abnormalities -- Retinal in vivo Abnormalities -- Retinal Nerve Abnormalities -- Retinal Vasculature Abnormalities -- Retinal Cellular Abnormalities - RGC Apoptosis -- NON-RETINAL OCULAR CHANGES IN AD -- AD-RELATED CHANGES IN RETINAL DISEASES -- AD-related Changes in Glaucoma -- AD-related Changes in AMD -- TARGETING OF AMYLOID-ß IN TREATMENT OF GLAUCOMA AND AMD -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Pathophysiology of Alzheimer Disease: Current Drug Therapy -- Sumeet Gupta* and Vikas Jhawat -- INTRODUCTION -- PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE -- HYPERTENSION AND ALZHEIMER'S DISEASE -- ROLE OF RENIN ANGIOTENSIN SYSTEM (RAS) IN ALZHEIMER'S DISEASE -- GENETIC POLYMORPHISM AND AD -- TREATMENTS FOR ALZHEIMER'S DISEASE -- HERBAL DRUGS FOR THE TREATMENT OF AD -- CONCLUSION -- ABBREVIATIONS: -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Biological Mass Spectrometry for Diagnosis of Alzheimer's Disease -- Hani Nasser Abdelhamid2,* and Hui-Fen Wu1,3,4,5,* -- INTRODUCTION -- Requirements of Alzheimer's Disease Diagnosis -- Application of Mass Spectrometry for Alzheimer's Disease -- Imaging Mass Spectrometry for Alzheimer's Disease -- Advantages and disadvantages of Mass Spectrometry -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Structure-Activity Relationship of Melanin as a Source of Energy Defines the Role of Glucose to Biomass Supply Only, Implications in the Context of the Failing Brain -- Arturo Solís Herrera* -- INTRODUCTION -- Basal Brain Energy Metabolism -- The Role of Pyridine Nucleotides and the Abnormal Expression of Genes -- REMARKS AND CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Neuro-protective Properties of the Fungus Isaria japonica: Evidence from a Mouse Model of Aged-related Degeneration -- Koichi Suzuki1,*, Masaaki Tsushima1, Masanobu Goryo2, Tetsuro Shinada3, Yoko Yasuno3, Eiji Nishimura3, Yasuo Terayama4, Yuki Mori5 and Yoshichika Yoshioka5 -- INTRODUCTION -- IJE Improves Nerve Function in Aged Mouse Brain -- 1. Neuroprotective Effects of IJE -- 2. Histochemical Observation -- 3. Assessments of Acute and Sub-acute Toxicity -- NMR Analyses in the I. Japonica Extract -- 1. Chemical Component of I. Japonica -- 2. Biologically Active Substances -- 3. NMR and Mass Study of Water Extract of I. Japonica -- Visualization of the Physiological and Pathological Alterations in the Central Nervous System using MRI and MRS -- 1. Fine Imaging Using Ultra-high Field MRI -- 2. Magnetic Resonance Spectroscopy -- 3. Brain Temperature Estimation Using MRS -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- SUBJECT INDEX. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Alzheimer's disease. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Atta-ur-Rahman |
| Title | Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 6 |
| Place, publisher, and date of publication | Sharjah : Bentham Science Publishers,c2017 |
| International Standard Book Number | 9781681083407 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Frontiers in Clinical Drug Research - Alzheimer Disorders |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5044184">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5044184</a> |
| Public note | Click to View |
No items available.